Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Artisan Global Discovery 2023 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Artisan Global Discovery)

Primary Source Intelligence • Q3 2023 Letter Analysis

Artisan Global Discovery Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Artisan Global Discovery. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+11.72%

Digest Analysis

Quick Take

"Global discovery fund delivered mixed Q3 results with biotechnology and software winners offset by payments sector weakness. Strong performance from Argenx FDA approvals and Atlassian cloud growth countered by Adyen competitive pressures and Shockwave margin concerns."

Executive Summary

Artisan Global Discovery Fund underperformed the MSCI AC World Index in September but was inline for Q3 2023. The portfolio benefited from strong performance in biotechnology and software holdings, particularly Argenx which saw FDA approval for its subcutaneous injection therapy and positive CIPD trial results, and Atlassian which delivered strong earnings and cloud business guidance. However, these gains were offset by weakness in payments company Adyen, where competitive pressure led to disappointing results and a position exit, and medical device company Shockwave, despite strong revenue growth, faced margin pressure from sales force investments. The fund maintains exposure to innovative companies across healthcare, technology, and other growth sectors, using a disciplined capital allocation process that builds position sizes according to conviction levels. Market conditions were challenging with rising inflation and higher interest rates, but the team continues to focus on companies with strong profit cycles and long-term competitive advantages.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through its concentrated approach with named top 10 holdings representing 35% of the portfolio. Specific position sizing decisions are discussed, including adding to Shockwave during weakness and exiting Adyen entirely. The three-stage Garden-Crop-Harvest process shows disciplined conviction building, though positions are not heavily concentrated in just a few names.

Growth Outlook

38%

BearishBullish

Neutral (38%)

The letter acknowledges challenging market conditions with rising inflation, higher-for-longer interest rates, and Treasury yields at 2007 highs. While not explicitly bearish, the tone suggests caution about the macro environment with Fed messaging about slow rate declines ahead.

Risk Appetite

10%

DefensiveAggressive

Defensive (10%)

The fund maintains its positions and selectively adds to holdings like Shockwave during weakness, suggesting modest risk appetite. However, the exit from Adyen due to competitive uncertainty shows some defensive positioning when conviction is lost.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Limited deployment activity with one position addition (Shockwave) and one exit (Adyen), representing rotation rather than net deployment. Cash level of 4.3% is mentioned but no comparison to prior periods is provided to assess net deployment direction.

Forward Guidance

0%

CautiousExpansionary

Cautious (0%)

No explicit forward guidance is provided about intended actions or deployment plans. The letter focuses on retrospective performance analysis without clear directional bias for future positioning.

Language Signal

5%

BearishBullish

Bearish (5%)

Language is balanced with both positive developments (FDA approvals, strong earnings) and negative factors (competitive pressure, margin concerns). Slightly more constructive given emphasis on adding to positions during weakness and excitement about long-term potential.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Moderate risk acknowledgment with discussion of inflation, interest rate concerns, and competitive pressures affecting specific holdings. Risks are identified and discussed but not presented as systemic threats requiring major defensive positioning.

Opportunity Density

55%

ScarceAbundant

Selective (55%)

The fund continues to find selective opportunities, adding to existing positions during weakness and maintaining a diversified portfolio across sectors. The ability to identify both winners and losers suggests reasonable opportunity identification, though no commentary on broader opportunity set abundance.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The fund demonstrates multi-year thinking with references to long-term potential, particularly for Shockwave, and willingness to hold through short-term volatility. The Garden-Crop-Harvest framework suggests a patient capital approach focused on profit cycle development over time rather than near-term catalysts.